[Therapeutic strategies in idiopatic inflammatory myopathies]
- PMID: 19441746
[Therapeutic strategies in idiopatic inflammatory myopathies]
Abstract
Idiopathic inflammatory myopathies, such as polymyositis and dermatomyositis, share common clinical features such as progressive, symmetrical muscle weakness prevailing in the lower limbs, associated sometimes with muscle pains. High CK and typical biopsy insure the diagnosis. Possible causes for secondary myopathies and associated diseases should be actively investigated. The search for autoantibodies helps to better classify inflammatory myopathies and to better define the prognosis of the myopathy. Glucocorticoids are the cornerstone of the early phase therapy. Glucocorticoid-sparing agents, such as azathioprine and methotrexate, are second line agents but can be readily prescribed. In case of therapeutic resistance, a rescue treatment (ciclosporine, immunoglobulins, rituximab, cyclophosphamide) could be considered.
Similar articles
-
[Dermatomyositis and polymyositis: clinical aspects and treatment].Ann Med Interne (Paris). 2001 Nov;152(7):455-64. Ann Med Interne (Paris). 2001. PMID: 11965087 French.
-
Inclusion body myositis: clinical and pathological boundaries.Ann Neurol. 1996 Oct;40(4):581-6. doi: 10.1002/ana.410400407. Ann Neurol. 1996. PMID: 8871577
-
[Inflammatory muscle diseases].Z Rheumatol. 1986 Jul-Aug;45(4):133-8. Z Rheumatol. 1986. PMID: 3776360 German.
-
Misunderstandings, misperceptions, and mistakes in the management of the inflammatory myopathies.Semin Neurol. 2002 Mar;22(1):41-51. doi: 10.1055/s-2002-33047. Semin Neurol. 2002. PMID: 12170392 Review.
-
Use of methotrexate in inflammatory myopathies.Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S164-7. Epub 2010 Oct 28. Clin Exp Rheumatol. 2010. PMID: 21044453 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials